Plant Advanced Technologies SA (ENXTPA: ALPAT)
Health Care · Biotechnology · FR
€4.32
-2.26% today · -52.5% 1Y
Plant Advanced Technologies SA (ENXTPA: ALPAT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.67M and employs 11 people.
Over the last twelve months the share price has lost 52.5%, trading between 3.98 and 9.30.
Tweenvest scores Plant Advanced Technologies SA across four factors: quality 63/100, value 50/100, growth 0/100. Its strongest factor is quality.
ALPAT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.67M
- Revenue (TTM)
- $1.94M
- P/E
- 8.47
- EPS
- 0.51
- Dividend yield
- —
- Beta (5Y)
- 0.83
- 52-week high
- €9.30
- 52-week low
- €3.98
- Avg volume (3M)
- —
- Shares outstanding
- 1.12M
- Employees
- 11
- Next earnings
- —
About Plant Advanced Technologies SA
Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. Its technologies include Process PAT Exudactive a sustainable sourcing solution to produce your exclusive, personalized Exudactive; and PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes. Plant Advanced Technologies SA was incorporated in 2005 and is headquartered in Vandœuvre-lès-Nancy, France.
- ISIN
- FR0010785790
- Founded
- 2005
- Listed since
- Sep 27, 2011
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.56 | +0.23% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.59 | +0.51% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.66 | +0.37% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $549.34 | +0.24% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.52 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.50 | -3.84% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.